Combined targeting of TGF-β1 and integrin β3 impairs lymph node metastasis in a mouse model of non-small-cell lung cancer

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Salvo, Elizabeth ^a   Garasa, Saray ^a   Dotor, Javier ^b   Morales, Xabier ^a   Peláez, Rafael ^a   Altevogt, Peter ^c   Rouzaut, Ana ^a,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Digna Biotech   (Spain)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Integrin; Lymph nodes; Lymphatic vessels; Metastases; TGF

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BETA3 INTEGRIN; DISITERTIDE; TRANSFORMING GROWTH FACTOR BETA1; CD31 ANTIGEN; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE L1; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL ADHESION; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPH VESSEL ENDOTHELIUM; MOUSE; NONHUMAN; PATIENT IDENTIFICATION; PROTEIN TARGETING; TUMOR CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; COCULTURE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTAXIS; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN BETA3; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; MOLECULAR TARGETED THERAPY; NEURAL CELL ADHESION MOLECULE L1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902109481     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-112     Document Type: Article

References (52)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
2. Milara J, Peiró T, Serrano A, Cortijo J. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax 2013, 68(5):410-420. 10.1136/thoraxjnl-2012-201761, 23299965.
3. Malkoski S, Haeger S, Cleaver T, Rodriguez K, Li H, Lu S, Feser W, Barón A, Merrick D, Lighthall J, Ijichi H, Franklin W, Wang X. Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma. Clin Cancer Res 2012, 18(8):2173-2183. 10.1158/1078-0432.CCR-11-2557, 3328594, 22399565.
4. Tian M, Neil J, Schiemann W. Transforming growth factor-ß and the hallmarks of cancer. Cell Signal 2011, 23(6):951-962. 10.1016/j.cellsig.2010.10.015, 3076078, 20940046.
5. Zamarron B, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011, 7(5):651-658. 3107473, 21647333.
6. Du S, Barcellos-Hoff MH. Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas. Semin Radiat Oncol 2013, 23(4):242-251. 10.1016/j.semradonc.2013.05.001, 24012338.
7. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013, 123(3):1348-1358. 10.1172/JCI65416, 3582135, 23391723.
8. Kawai H, Minamiya Y, Ito M, Saito H, Ogawa J. VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients. Lung Cancer 2008, 59(1):41-47. 10.1016/j.lungcan.2007.08.001, 17868952.
9. Wang J, Guo Y, Wang B, Bi J, Li K, Liang X, Chu H, Jiang H. Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. Mol Biol Rep 2012, 39(12):11153-11165. 10.1007/s11033-012-2024-y, 23054001.
10. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, Takenoyama M, Hanagiri T, Oyama T, Yasumoto K. Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 2010, 70(3):320-328. 10.1016/j.lungcan.2010.02.013, 20363046.
11. Zigrino P, Löffek S, Mauch C. Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie 2005, 87(3-4):321-328.
12. Irigoyen M, Pajares M, Agorreta J, Ponz-Sarvisé M, Salvo E, Lozano M, Pío R, Gil Bazo I, Rouzaut A. TGFBI expression is associated with a better response to chemotherapy in NSCLC. Mol Cancer 2010, 9:130-130. 10.1186/1476-4598-9-130, 2900244, 20509890.
13. Azzali G. The modality of transendothelial passage of lymphocytes and tumor cells in the absorbing lymphatic vessel. Eur J Histochem 2007, 51(Suppl 1):73-77.
14. Pflicke H, Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J Exp Med 2009, 206(13):2925-2935. 10.1084/jem.20091739, 2806476, 19995949.
15. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004, 25(7):387-395. 10.1016/j.it.2004.05.003, 15207507.
16. Lämmermann T, Bader BL, Monkley SJ, Worbs T, Wedlich-Söldner R, Hirsch K, Keller M, Förster R, Critchley DR, Fässler R, Sixt M. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 2008, 453(7191):51-55. 10.1038/nature06887, 18451854.
17. Yao LC, Baluk P, Srinivasan RS, Oliver G, McDonald DM. Plasticity of button-like junctions in the endothelium of airway lymphatics in development and inflammation. Am J Pathol 2012, 180(6):2561-2575. 10.1016/j.ajpath.2012.02.019, 3378913, 22538088.
18. Johnson LA, Jackson DG. Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. Int Immunol 2010, 22(10):839-849. 10.1093/intimm/dxq435, 20739459.
19. Rouzaut A, Garasa S, Teijeira T, González I, Martinez-Forero I, Suarez N, Larrea E, Alfaro C, Palazón A, Dubrot J, Hervás-Stubbs S, Melero I. Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α. Eur J Immunol 2010, 40(11):3054-3063. 10.1002/eji.201040523, 21061437.
20. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39(1):11-26. 10.1016/j.immuni.2013.07.008, 23890060.
21. Kawashima A, Tsugawa S, Boku A, Kobayashi M, Minamoto T, Nakanishi I, Oda Y. Expression of αv integrin family in gastric carcinomas: increased αvβ6 is associated with lymph node metastasis. Pathol Res Pract 2003, 199(2):57-64. 10.1078/0344-0338-00355, 12747466.
22. Li F, Liu Y, Kan X, Li Y, Liu M, Lu JG. Elevated expression of integrin αv and β5 subunit in laryngeal squamous-cell carcinoma associated with lymphatic metastasis and angiogenesis. Pathol Res Pract 2013, 209(2):105-109. 10.1016/j.prp.2012.11.001, 23261238.
23. Irigoyen M, Ansó E, Martínez E, Garayoa M, Martínez Irujo JJ, Rouzaut A. Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochim Biophys Acta 2007, 1773(6):880-890. 10.1016/j.bbamcr.2007.03.001, 17442415.
24. Martínez-García E, Irigoyen M, González-Moreno T, Corrales L, Teijeira T, Salvo E, Rouzaut A. Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci 2010, 116(2):467-476. 10.1093/toxsci/kfq138, 20457658.
25. Wolterink S, Moldenhauer G, Fogel M, Kiefel H, Pfeifer M, Lüttgau S, Gouveia R, Costa J, Endell J, Moebius U, Altevogt P. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res 2010, 70(6):2504-2515. 10.1158/0008-5472.CAN-09-3730, 20215505.
26. Doki Y, Murakami K, Yamaura T, Sugiyama S, Misaki T, Saiki I. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer 1999, 79(7-8):1121-1126. 2362254, 10098745.
27. Muñoz-Barrutia A, Ceresa M, Artaechevarria X, Montuenga LM, Ortiz-de-Solorzano C. Quantification of lung damage in an elastase-induced mouse model of emphysema. Int J Biomed Imag 2012, 2012:734734-734734.
28. Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol 2010, 188(1):11-19. 10.1083/jcb.200909003, 2812848, 19951899.
29. Padua D, Massague J. Roles of TGFbeta in metastasis. Cell Res 2009, 19(1):89-102. 10.1038/cr.2008.316, 19050696.
30. Ezquerro I, Lasarte J, Dotor J, Castilla-Cortázar I, Bustos M, Peñuelas I, Blanco G, Rodríguez C, Lechuga MCG, Greenwel P, Rojkind M, Prieto J, Borrás-Cuesta F. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 2003, 22(1-2):12-20.
31. Schäfer H, Dieckmann C, Korniienko O, Moldenhauer G, Kiefel H, Salnikov A, Krüger A, Altevogt P, Sebens S. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett 2012, 319(1):66-82. 10.1016/j.canlet.2011.12.035, 22210381.
32. Weinspach D, Seubert B, Schaten S, Honert K, Sebens S, Altevogt P, Krüger A. Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. Clin Exp Metastasis 2014, 31(1):87-100. 10.1007/s10585-013-9613-6, 24002299.
33. Connolly E, Freimuth J, Akhurst R. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 2012, 8(7):964-978. 10.7150/ijbs.4564, 3399319, 22811618.
34. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003, 3(5):362-374. 10.1038/nrc1075, 12724734.
35. Mamuya FA, Duncan MK. aV integrins and TGF-β-induced EMT: a circle of regulation. J Cell Mol Med 2012, 16(3):445-455. 10.1111/j.1582-4934.2011.01419.x, 3290750, 21883891.
36. Pechkovsky DV, Scaffidi AK, Hackett TL, Ballard J, Shaheen F, Thompson PJ, Thannickal VJ, Knight DA. Transforming growth factor beta1 induces alphavbeta3 integrin expression in human lung fibroblasts via a beta3 integrin-, c-Src-, and p38 MAPK-dependent pathway. J Biol Chem 2008, 283(19):12898-12908. 10.1074/jbc.M708226200, 18353785.
37. Marchán S, Pérez-Torras S, Vidal A, Adan J, Mitjans F, Carbó N, Mazo A. Dual effects of β3 integrin subunit expression on human pancreatic cancer models. Anal Cell Pathol 2010, 33(5):191-205.
38. Takayama S, Ishii S, Ikeda T, Masamura S, Doi M, Kitajima M. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression. Anticancer Res 2005, 25(1A):79-83.
39. Tome Y, Kimura H, Maehara H, Sugimoto N, Bouvet M, Tsuchiya H, Kanaya F, Hoffman RM. High lung-metastatic variant of human osteosarcoma cells, selected by passage of lung metastasis in nude mice, is associated with increased expression of α(v)β(3) integrin. Anticancer Res 2013, 33(9):3623-3627.
40. Voura EB, Ramjeesingh RA, Montgomery AM, Siu CH. Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell 2001, 12(9):2699-2710. 10.1091/mbc.12.9.2699, 59705, 11553709.
41. Issa Y, Nummer D, Seibel T, Müerköster S, Koch M, Schmitz Winnenthal F, Galindo L, Weitz J, Beckhove P, Altevogt P. Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J Mol Med 2009, 87(1):99-112. 10.1007/s00109-008-0410-7, 18931829.
42. Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P, Schito L, Chen J, Krishnamachary B, Winnard PT, Raman V, Zhen L, Mitzner WA, Sukumar S, Semenza GL. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012, 31(14):1757-1770. 10.1038/onc.2011.365, 3223555, 21860410.
43. Worthington JJ, Klementowicz JE, Travis MA. TGFβ: a sleeping giant awoken by integrins. Trends Biochem Sci 2011, 36(1):47-54. 10.1016/j.tibs.2010.08.002, 20870411.
44. Albert J, Cao C, Geng L, Leavitt L, Hallahan D, Lu B. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006, 65(5):1536-1543. 10.1016/j.ijrobp.2006.04.036, 16863930.
45. Díaz-Valdés N, Basagoiti M, Dotor J, Aranda F, Monreal I, Riezu Boj J, Borrés-Cuesta F, Sarobe P, Feijoó E. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFbeta1 in melanoma enhances tumor infiltration and immunosuppression. Cancer Res 2011, 71(3):812-821. 10.1158/0008-5472.CAN-10-2698, 21159663.
46. Serratì S, Margheri F, Pucci M, Cantelmo AR, Cammarota R, Dotor J, Borràs-Cuesta F, Fibbi G, Albini A, Del Rosso M. TGFbeta1 antagonistic peptides inhibit TGFbeta1-dependent angiogenesis. Biochem Pharmacol 2009, 77(5):813-825. 10.1016/j.bcp.2008.10.036, 19041849.
47. Zubeldia IG, Bleau AM, Redrado M, Serrano D, Agliano A, Gil-Puig C, Vidal-Vanaclocha F, Lecanda J, Calvo A. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFβ1-targeting peptides P17 and P144. Exp Cell Res 2013, 319(3):12-22.
48. Llopiz D, Dotor J, Casares N, Bezunartea J, Díaz-Valdés N, Ruiz M, Aranda F, Berraondo P, Prieto J, Lasarte J, Borrás-Cuesta F, Sarobe P. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 2009, 125(11):2614-2623. 10.1002/ijc.24656, 19530254.
49. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci 2012, 8(7):964-978. 10.7150/ijbs.4564, 3399319, 22811618.
50. Yang Z, Mu Z, Dabovic B, Jurukovski V, Yu D, Sung J, Xiong X, Munger JS. Absence of integrin-mediated TGFbeta1 activation in vivo recapitulates the phenotype of TGFbeta1-null mice. J Cell Biol 2007, 176(6):787-793. 10.1083/jcb.200611044, 2064053, 17353357.
51. Perrot CY, Javelaud D, Mauviel A. Overlapping activities of TGF-β and Hedgehog signaling in cancer: therapeutic targets for cancer treatment. Pharmacol Ther 2013, 137(2):183-199. 10.1016/j.pharmthera.2012.10.002, 23063491.
52. Parvani JG, Galliher-Beckley AJ, Schiemann BJ, Schiemann WP. Targeted inactivation of β1 integrin induces β3 integrin switching that drives breast cancer metastasis by TGF-β. Mol Biol Cell 2013, 24(21):3449-3459. 10.1091/mbc.E12-10-0776, 3814150, 24006485.